• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

抗体依赖性增强（ADE）作用：鉴定关键氨基酸在登革热疫苗研究中的重要性。

Antibody-dependent enhancement (ADE) of dengue virus: Identification of the key amino acid that is vital in DENV vaccine research.

机构信息

Key Laboratory for Tropic Diseases Control, Ministry of Education of China, Department of Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.

Department of Gynaecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou City, Henan Province, China.

出版信息

J Gene Med. 2021 Feb;23(2):e3297. doi: 10.1002/jgm.3297. Epub 2021 Jan 17.

DOI:10.1002/jgm.3297
PMID:33217097
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7900978/
Abstract

BACKGROUND

The antibody-dependent enhancement (ADE) of dengue virus (DENV) has critically restricted vaccine development. Prior research suggested pr4 as the probable ADE epitope of DENV.

METHODS

Chimeric DENV was constructed by replacing the DENV pr4 gene with the corresponding Japanese encephalitis virus (JEV) gene to determine whether it can reduce ADE activities. An alanine scanning method and bioinformatics analysis were utilized to identify the amino acid of pr4 that was crucial as an ADE epitope.

RESULTS

Chimeric virus reduced ADE and virulence. The amino acids at the following locations on the mutant peptides showed significantly reduced binding ability to prM antibody: pr4.5 (position 5 - leucine), pr4.6 (position 6 - leucine), pr4.7 (position 7 - phenyalanine) and pr4.16 (position 16 - cysteine). The four amino acids had formed a pocket-like structure, which could increase the possibility of binding to an antibody.

CONCLUSIONS

ADE activities could be reduced by replacing the DENV pr4 gene with the corresponding JEV gene. Leucine at position 5, leucine at position 6, phenyalanine at position 7 and cysteine at position 16 were the key amino acid sites in the ADE response of DENV. The occurrence of ADE can potentially be reduced by the replacement of key amino acids, hence highlighting its possible contribution to dengue vaccine design, paving a way for future vaccine research.

摘要

背景

登革热病毒（DENV）的抗体依赖性增强（ADE）极大地限制了疫苗的开发。先前的研究表明 pr4 是 DENV 的可能 ADE 表位。

方法

通过用相应的日本脑炎病毒（JEV）基因替换 DENV pr4 基因来构建嵌合 DENV，以确定它是否可以降低 ADE 活性。采用丙氨酸扫描法和生物信息学分析来鉴定作为 ADE 表位的关键 pr4 氨基酸。

结果

嵌合病毒降低了 ADE 和毒力。突变肽中以下位置的氨基酸显示与 prM 抗体的结合能力显著降低：pr4.5（位置 5-亮氨酸）、pr4.6（位置 6-亮氨酸）、pr4.7（位置 7-苯丙氨酸）和 pr4.16（位置 16-半胱氨酸）。这四个氨基酸形成了一个口袋样结构，增加了与抗体结合的可能性。

结论

用相应的 JEV 基因替换 DENV pr4 基因可降低 ADE 活性。位置 5 的亮氨酸、位置 6 的亮氨酸、位置 7 的苯丙氨酸和位置 16 的半胱氨酸是 DENV ADE 反应中的关键氨基酸位点。通过替换关键氨基酸，可能会降低 ADE 的发生，因此强调了其在登革热疫苗设计中的可能贡献，为未来的疫苗研究铺平了道路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7da/7900978/252a071593b2/JGM-23-e3297-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7da/7900978/c4e884bef896/JGM-23-e3297-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7da/7900978/4d9ba1d9182f/JGM-23-e3297-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7da/7900978/b1ce0229f115/JGM-23-e3297-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7da/7900978/4fd8e7f586b9/JGM-23-e3297-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7da/7900978/74da094174f3/JGM-23-e3297-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7da/7900978/ca7960320554/JGM-23-e3297-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7da/7900978/56f1321e33fd/JGM-23-e3297-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7da/7900978/a8b37d584a0d/JGM-23-e3297-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7da/7900978/b97614b2c4fd/JGM-23-e3297-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7da/7900978/252a071593b2/JGM-23-e3297-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7da/7900978/c4e884bef896/JGM-23-e3297-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7da/7900978/4d9ba1d9182f/JGM-23-e3297-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7da/7900978/b1ce0229f115/JGM-23-e3297-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7da/7900978/4fd8e7f586b9/JGM-23-e3297-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7da/7900978/74da094174f3/JGM-23-e3297-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7da/7900978/ca7960320554/JGM-23-e3297-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7da/7900978/56f1321e33fd/JGM-23-e3297-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7da/7900978/a8b37d584a0d/JGM-23-e3297-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7da/7900978/b97614b2c4fd/JGM-23-e3297-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7da/7900978/252a071593b2/JGM-23-e3297-g010.jpg

相似文献

1
Antibody-dependent enhancement (ADE) of dengue virus: Identification of the key amino acid that is vital in DENV vaccine research.抗体依赖性增强（ADE）作用：鉴定关键氨基酸在登革热疫苗研究中的重要性。
J Gene Med. 2021 Feb;23(2):e3297. doi: 10.1002/jgm.3297. Epub 2021 Jan 17.
2
Replacement of pr gene with Japanese encephalitis virus pr using reverse genetics reduces antibody-dependent enhancement of dengue virus 2 infection.使用反向遗传学技术将登革病毒2的pr基因替换为日本脑炎病毒的pr基因可降低登革病毒2感染的抗体依赖性增强作用。
Appl Microbiol Biotechnol. 2015 Nov;99(22):9685-98. doi: 10.1007/s00253-015-6819-3. Epub 2015 Jul 29.
3
Substitution of the precursor peptide prevents anti-prM antibody-mediated antibody-dependent enhancement of dengue virus infection.前体肽的取代可防止抗前膜蛋白抗体介导的登革病毒感染的抗体依赖性增强作用。
Virus Res. 2017 Feb 2;229:57-64. doi: 10.1016/j.virusres.2016.12.003. Epub 2016 Dec 6.
4
Comprehensive mapping infection-enhancing epitopes of dengue pr protein using polyclonal antibody against prM.使用抗prM多克隆抗体全面绘制登革病毒pr蛋白的感染增强表位。
Appl Microbiol Biotechnol. 2015 Jul;99(14):5917-27. doi: 10.1007/s00253-015-6538-9. Epub 2015 Mar 31.
5
Anti-Idiotypic Antibodies Specific to prM Monoantibody Prevent Antibody Dependent Enhancement of Dengue Virus Infection.针对prM单克隆抗体的抗独特型抗体可预防登革病毒感染的抗体依赖性增强。
Front Cell Infect Microbiol. 2017 May 9;7:157. doi: 10.3389/fcimb.2017.00157. eCollection 2017.
6
Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults.成人中乙脑疫苗促进的登革病毒感染增强抗体
BMC Infect Dis. 2016 Oct 18;16(1):578. doi: 10.1186/s12879-016-1873-8.
7
The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.四价登革热DNA疫苗对预先接触过日本脑炎或登革热病毒抗原的小鼠的免疫原性。
Asian Pac J Allergy Immunol. 2015 Sep;33(3):182-8. doi: 10.12932/AP0508.33.3.2015.
8
Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.具有工程化Fc区域的抗体作为抗登革病毒感染的治疗剂。
Antiviral Res. 2015 Dec;124:61-8. doi: 10.1016/j.antiviral.2015.10.012. Epub 2015 Oct 30.
9
Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models.登革热和 Zika 病毒感染可被减毒活疫苗增强，但在小鼠模型中，重组 DSV4 候选疫苗不会增强登革热感染。
EBioMedicine. 2020 Oct;60:102991. doi: 10.1016/j.ebiom.2020.102991. Epub 2020 Sep 16.
10
Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response.评估由日本脑炎和登革热病毒的前膜和包膜基因组成的嵌合 DNA 疫苗作为减少登革热病毒感染增强抗体反应的策略。
Microbiol Immunol. 2014 Feb;58(2):126-34. doi: 10.1111/1348-0421.12125.

引用本文的文献

1
Anti-pA137R antibodies exacerbate the pathogenicity of African swine fever virus in pigs.抗pA137R抗体加剧非洲猪瘟病毒在猪身上的致病性。
J Virol. 2025 Jun 17;99(6):e0017225. doi: 10.1128/jvi.00172-25. Epub 2025 May 29.
2
Development of New Live-Attenuated Vaccine Candidates Lacking Antibody-Dependent Enhancement (ADE) Against Dengue.新型登革热减毒活疫苗候选株的研发：无抗体依赖增强（ADE）作用
Vaccines (Basel). 2025 May 16;13(5):532. doi: 10.3390/vaccines13050532.
3
The antibodies against the A137R protein drive antibody-dependent enhancement of African swine fever virus infection in porcine alveolar macrophages.

本文引用的文献

1
Long-Term Protection Elicited by a DNA Vaccine Candidate Expressing the prM-E Antigen of Dengue Virus Serotype 3 in Mice.DNA 疫苗候选物表达登革病毒 3 型 prM-E 抗原在小鼠中诱导的长期保护作用。
Front Cell Infect Microbiol. 2020 Mar 17;10:87. doi: 10.3389/fcimb.2020.00087. eCollection 2020.
2
Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus.基于结构的登革病毒包膜糖蛋白抗病毒药物设计。
Viruses. 2020 Mar 26;12(4):367. doi: 10.3390/v12040367.
3
Enhanced production of infectious particles by adaptive modulation of C-prM processing and C-C interaction during propagation of dengue pseudoinfectious virus in stable CprME-expressing cells.
针对 A137R 蛋白的抗体可驱动非洲猪瘟病毒在猪肺泡巨噬细胞中的抗体依赖性增强感染。
Emerg Microbes Infect. 2024 Dec;13(1):2377599. doi: 10.1080/22221751.2024.2377599. Epub 2024 Jul 18.
4
Comparative Analysis of In Vitro Models to Study Antibody-Dependent Enhancement of Zika Virus Infection.比较分析体外模型以研究寨卡病毒感染的抗体依赖性增强作用。
Viruses. 2022 Dec 13;14(12):2776. doi: 10.3390/v14122776.
5
Antibody-Dependent Enhancement: ″Evil″ Antibodies Favorable for Viral Infections.抗体依赖增强作用：有利于病毒感染的“邪恶”抗体。
Viruses. 2022 Aug 8;14(8):1739. doi: 10.3390/v14081739.
6
A multiple-target mRNA-LNP vaccine induces protective immunity against experimental multi-serotype DENV in mice.一种多靶标 mRNA-LNP 疫苗可诱导小鼠对实验性多血清型登革热产生保护性免疫。
Virol Sin. 2022 Oct;37(5):746-757. doi: 10.1016/j.virs.2022.07.003. Epub 2022 Jul 12.
7
Genotype-Dependent Immunogenicity of Dengue Virus Type 2 Asian I and Asian/American Genotypes in Common Marmoset (: Discrepancy in Neutralizing and Infection-Enhancing Antibody Levels between Genotypes.登革病毒2型亚洲I基因型和亚洲/美洲基因型在普通狨猴中的基因型依赖性免疫原性：基因型之间中和抗体和感染增强抗体水平的差异
Microorganisms. 2021 Oct 21;9(11):2196. doi: 10.3390/microorganisms9112196.
8
Antibody dependent enhancement: Unavoidable problems in vaccine development.抗体依赖增强作用：疫苗开发中不可避免的问题。
Adv Immunol. 2021;151:99-133. doi: 10.1016/bs.ai.2021.08.003. Epub 2021 Sep 14.
9
A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies.综述：COVID-19 中的抗体依赖性增强作用：抗体不那么友好的一面。
Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211050199. doi: 10.1177/20587384211050199.
10
Influence of obesity on serum levels of SARS-CoV-2-specific antibodies in COVID-19 patients.肥胖对 COVID-19 患者血清中 SARS-CoV-2 特异性抗体水平的影响。
PLoS One. 2021 Mar 24;16(3):e0245424. doi: 10.1371/journal.pone.0245424. eCollection 2021.
在稳定表达CprME的细胞中登革热假感染病毒传播期间，通过适应性调节C-prM加工和C-C相互作用增强感染性颗粒的产生。
J Gen Virol. 2020 Jan;101(1):59-72. doi: 10.1099/jgv.0.001345.
4
Dengue infection and advances in dengue vaccines for children.登革热感染和儿童登革热疫苗的进展。
Lancet Child Adolesc Health. 2019 Oct;3(10):734-741. doi: 10.1016/S2352-4642(19)30205-6. Epub 2019 Aug 1.
5
Japanese encephalitis virus prM-E antigen immunization conferred protection against challenge by four different serotypes of Dengue viruses in mice.日本脑炎病毒 prM-E 抗原免疫可预防小鼠感染四种不同血清型登革热病毒。
Appl Microbiol Biotechnol. 2019 Jun;103(12):4977-4986. doi: 10.1007/s00253-019-09798-9. Epub 2019 Apr 29.
6
Dengue Fever: A Worldwide Threat An Overview of the Infection Process, Environmental Factors for a Global Outbreak, Diagnostic Platforms and Vaccine Developments.登革热：全球威胁概述 感染过程、全球爆发的环境因素、诊断平台和疫苗开发。
Curr Top Med Chem. 2018;18(18):1531-1549. doi: 10.2174/1568026618666181105130000.
7
Disease and economic burdens of dengue.登革热的疾病负担和经济负担。
Lancet Infect Dis. 2017 Mar;17(3):e70-e78. doi: 10.1016/S1473-3099(16)30545-X. Epub 2017 Feb 7.
8
Relative contribution of dengue prM- and E-specific polyclonal antibodies to neutralization and enhancement.
Acta Virol. 2016;60(3):249-59. doi: 10.4149/av_2016_03_249.
9
Dengue Fever: Causes, Complications, and Vaccine Strategies.登革热：病因、并发症及疫苗策略
J Immunol Res. 2016;2016:6803098. doi: 10.1155/2016/6803098. Epub 2016 Jul 20.
10
Strategies to improve the immunogenicity of prM+E dengue virus type-2 DNA vaccine.提高 prM+E 登革病毒 2 型 DNA 疫苗免疫原性的策略。
Asian Pac J Allergy Immunol. 2017 Mar;35(1):11-19. doi: 10.12932/AP0728.